Chronic low‑grade pain activates stress pathways that, at sub‑noxious intensities, stimulate Nrf2‑mediated antioxidant responses, autophagy, and immune surveillance that together promote senescent cell clearance. When analgesics blunt these signals, the body loses a critical cue for directing repair mechanisms toward damaged cells, allowing senescent cells to persist and fuel a feed‑forward loop of inflammation and tissue degeneration. We hypothesize that long‑term pharmacological pain relief reduces the activation of Nrf2 and downstream autophagy flux in peripheral tissues, diminishes ATP‑dependent P2X7 inflammasome signaling in glial cells, and consequently weakens NKG2D/DNAM1‑mediated NK‑cell cytotoxicity toward senescent dorsal root ganglion (DRG) neurons. This mechanistic deficit leads to higher senescent cell burden, increased SASP secretion, and accelerated biological aging markers despite short‑term pain relief.

To test this, we propose a two‑arm human observational study matched for age, pain severity, and comorbidities: (1) participants receiving chronic opioid or NSAID therapy (>6 months) and (2) participants managing comparable pain through non‑pharmacological strategies (graded exercise, cognitive‑behavioral therapy, or acupuncture). Peripheral blood will be assayed for senescent T‑cell frequency (p16INK4a^+ CD4^+, p21^Cip1^+ CD8^+), plasma SASP factors (IL‑6, IL‑8, MMP‑3), and Nrf2 target gene expression (NQO1, HO‑1) in isolated monocytes. We predict the analgesic group will show significantly higher senescent cell frequencies and SASP levels, alongside lower Nrf2 target expression, compared to the non‑pharmacological group (p<0.01, effect size d>0.8).

In parallel, we will use a murine model of neuropathic pain (spared nerve injury) treated with either morphine or vehicle. Flow cytometry of DRG‑resident NK cells will assess NKG2D surface density and degranulation (CD107a^+) toward co‑cultured senescent DRG neurons identified by p21^Cip1^+ staining. Morphine‑treated mice are expected to exhibit reduced NKG2D expression and diminished NK‑cell killing, resulting in greater accumulation of p21^Cip1^+ DRG neurons and heightened mechanical hypersensitivity over 4 weeks (repeated‑measures ANOVA, interaction p<0.05). Rescue experiments with senolytic agents (dasatinib+quercetin) should normalize pain behaviors only in the analgesic‑treated mice, confirming that senescent cell persistence mediates the analgesic‑induced aging phenotype.

Falsifiable outcomes: If analgesic users do not exhibit elevated senescent cell biomarkers or if NK‑cell cytotoxicity remains unchanged despite opioid exposure, the hypothesis would be refuted. Conversely, confirmation would support re‑evaluating analgesic protocols to preserve pain‑derived stress signaling as a regenerative cue, perhaps by dosing regimens that allow intermittent breakthrough pain or by co‑administering agents that boost Nrf2 or NK‑cell function without compromising analgesia.